Recent developments in the epidemiology, diagnosis, treatment, and prevention of neurocysticercosis
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Neuroimaging studies have revealed that neurocysticercosis is a major cause of neurologic disease in most developing countries and is an emerging disease in industrialized areas. Patients with neurocysticercosis present mainly with seizures (parenchymal form) or intracranial hypertension (ventricular/subarachnoid forms). Management should be based on a thorough understanding of the pathogenesis and natural history of infection. Symptoms of active parenchymal neurocysticercosis result from the host inflammatory response to the dying metacestode form. Careful use of anticonvulsants will result in an excellent clinical outcome. The anthelminthic drugs albendazole and praziquantel are effective in killing the cysts, but their long-term effect on prognosis is unproven. Patients with obstructive hydrocephalus from ventricular cysts should be managed surgically by cerebrospinal fluid diversion or cyst removal. Treatment with antiparasitic drugs (especially albendazole) and corticosteroids may decrease the incidence of shunt failure. Current efforts at control of the disease include mass human or porcine chemotherapy in endemic zones and vaccination.
- White Jr AC: State-of-the-art. Neurocysticercosis: a common cause of neurologic disease worldwide. Clin Infect Dis 1997, 24:101–113. A recent detailed review of neurocysticercosis that includes some US data.
- Sousa AQ, Sa HL, Queiroz TR, et al.: Neurocysticercosis in Ceara State, northern Brazil: a review of 119 cases. Am J Trop Med Hyg 1998, 58:759–762.
- Palacio LG, Jimenez I, Garcia HH, et al.: Neurocysticercosis in persons with epilepsy in Medellin, Colombia: the neuroepidemiological research group of Antioquia. Epilepsia 1998, 39:1334–1339. CrossRef
- Garcia-Noval J, Allan JC, Fletes C, et al.: Epidemiology of Taenia solium taeniasis and cysticercosis in two rural Guatemalan communities. Am J Trop Med Hyg 1996, 55:282–289.
- Jafri HS, Torrico F, Noh JC, et al.: Application of the enzymelinked immunoelectrotransfer blot to filter paper blood spots to estimate seroprevalence of cysticercosis in Bolivia. Am J Trop Med Hyg 1998, 58:313–315.
- Newell E Vyungimana F, Geerts S, et al.: Prevalence of cysticercosis in epileptics and members of their families in Burundi. Trans R Soc Trop Med Hyg 1997, 91:389–391. CrossRef
- Andriantsimahavandy A, Lesbordes JL, Rasoaharimalala B, et al.: Neurocysticercosis: a major aetiological factor of late-onset epilepsy in Madagascar. Trop Med Int Health 1997, 2:741–746. CrossRef
- Murthy JMK, Yangala R: Etiological spectrum of symptomatic localization related epilepsies: a study from South India. J Neurol Sci 1998, 158:65–70. A study of the etiology of nearly 1000 cases of seizures from India illustrating the spectrum of neuroradiologic findings and the importance of neurocysticercosis. CrossRef
- Rajshekhar V, Chandy MJ: Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures. Acta Neurol Scand 1997, 96:76–81. A careful study of patients with seizures and single enhancing lesions demonstrating the reliability of criteria for diagnosing cysticercal granulomas. CrossRef
- Salgado P, Rojas R, Sotelo J: Cysticercosis: clinical classification based on imaging studies. Arch Intern Med 1997, 157:1991–1997. CrossRef
- White Jr AC, Robinson P, Kuhn R: Taenia solium cysticercosis: host-parasite interactions and the immune response. In Immunopathogenetic Aspects of Disease Induced by Helminth Parasites. Edited by Freedman DO. Basel: S. Karger AG; 1997:209–230. CrossRef
- Restrepo BI, Llaguno P, Sandoval MA, et al.: Analysis of immune lesions in neurocysticercosis patients: central nervous system response to helminth appears Th1-like instead of Th2. J Neuroimmunol 1998, 89:64–72. CrossRef
- Pittella JEH: Neurocysticercosis. Brain Pathol 1997, 7:681–693.
- Cruz ME, Cruz I, Preux P-M, et al.: Headaches and cysticercosis in Ecuador, South America. Headache 1995, 35:93–97. CrossRef
- Ruiz-Garcia M, Gonzalez-Astiazaran A, Rueda-Franco R: Neurocysticercosis in children: clinical experience in 122 patients. Am J Trop Med 1997, 13:608–612.
- Forlenza OV, Filho AHGV, Nobrega JPS, et al.: Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 1997, 62:612–616.
- Sheth TN, Pilon L, Keystone J, et al.: Persistent MR contrast enhancement of calcified neurocysticercosis lesions. AJNR Am J Neuroradiol 1998, 19:79–82. This study documents cases with contrast enhancement on neuroimaging studies that otherwise only have calcifications. This points to the importance of host inflammation in seizures in patients with inactive infection.
- Sheth TN, Lee C, Kucharczyk W, et al.: Reactivation of neurocysticercosis: case report. Am J Trop Med Hyg 1999, 60:664–667.
- Gupta RK, Kathuria MK, Pradhan S: Magnetisation transfer magnetic resonance imaging demonstration of perilesional gliosis: relation with epilepsy in treated or healed neurocysticercosis [letter]. Lancet 1999, 354:44–45. CrossRef
- Barinagarrementeria F, Cantu C: Frequency of cerebral arteritis in subarachnoid cysticercosis: an angiographic study. Stroke 1998, 29:123–125.
- Cantú C, Barinagarrementeria MD: Cerebrovascular complications of neurocysticercosis: clinical and neuroimagining spectrum. Arch Neurol 1996, 53:233–239.
- Kohli A, Gupta R, Kishore J: Anterior cerebral artery territory infarction in neurocysticercosis: evaluation by MR angiography and in vivo proton MR spectroscopy. Pediatr Neurosurg 1997, 26:93–96. CrossRef
- Del Brutto OH, Wadia NH, Dumas M, et al.: Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci 1996, 142:1–6. This article describes diagnostic criteria for cysticercosis that are increasingly recognized as the standard. CrossRef
- Dumas JL, Visy JM, Belin C, et al.: Parenchymal neurocysticercosis: followup and staging by MRI. Neuroradiology 1997, 39:12–18. CrossRef
- Garcia HH, Harrison LJ, Parkhouse RM, et al.: A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis: the Cysticercosis Working Group in Peru. Trans R Soc Trop Med Hyg 1998, 92:411–414. CrossRef
- Carpio A, Escobar A, Hauser WA: Cysticercosis and epilepsy: a critical review. Epilepsia 1998, 39:1025–1040. This thoughtful article comprehensively reviews the epidemiology, clinical manifestations, and treatment of neurocysticercosis. CrossRef
- Sotelo J, Jung H: Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 1998, 34:503–515. CrossRef
- Yee T, Barakos JA, Knight RT: High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med 1999, 170:112–115.
- Garcia HH, Gilman RH, Horton J, et al.: Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment: Cysticercosis Working Group in Peru. Neurology 1997, 48:1421–1427.
- Evans C, Garcia HH, Gilman RH, et al.: Controversies in the management of cysticercosis. Emerg Infect Dis 1997, 3:403–405. CrossRef
- Salinas R, Prasad K: Drugs for treating neurocysticercosis (tapeworm infection of the brain) [Cochrane review]. The Cochrane Library 1999, 1:http://www.updateusa.com/ cochrane.html. This systematic review is part of the Cochrane Library, which applies the principles of evidence-based medicine to therapeutic questions. The Cochrane Library is published primarily electronically and is available via the Internet. This article systematically reviews trials of antiparasitic treatment of neurocysticercosis. None of the trials reviewed demonstrated convincing evidence of clinical benefit.
- Carpio A, Santillán F, León P, et al.: Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995, 155:1982–1988. This is the largest randomized controlled trial of anthelminthic therapy in neurocysticercosis. It demonstrated that even though lesions on neuroimaging studies tended to resolve more rapidly with antiparasitic drugs, there was no significant difference in clinical outcome. CrossRef
- Baranwal AK, Singhi PD, Khandelwal N, et al.: Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr Infect Dis J 1998, 7:696–700. This report of a recent randomized, placebo-controlled trial noted no difference in overall clinical endpoints or of development of cerebral calcifications. Patients treated with albendazole, however, had a more rapid resolution of imaging studies and a shift in seizures to earlier time points.
- Corona T, Lugo R, Medina R, et al.: Single-day praziquantel therapy for neurocysticercosis. N Engl J Med 1996, 334:125. CrossRef
- Del Brutto OH, Campos X, Sanchez J, et al.: Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 1999, 52:1079–1081.
- Proano JV, Madrazo I, Garcia L, et al.: Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. J Neurosurg 1997, 87:29–33. This study describes the medical treatment of 10 patients with fourth ventricular neurocysticercosis. CrossRef
- Cuetter A, Garcia-Bobadilla J, Guerra L, et al.: Neurocysticercosis: focus on intraventricular disease. Clin Infect Dis 1997, 24:157–164.
- Del Brutto OH: Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J Neurol Neurosurg Psychiatry 1997, 62:659–661. This article reports a case series of patients with subarachnoid cysticercosis who improved with albendazole therapy. While uncontrolled, the data suggest a role for antiparasitic drugs in this form of disease.
- Suastegui Roman R, Soto-Hernandez J, Sotelo J: Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 1996, 84:629–633.
- Sotelo J, Rubalcava MA, Gomez-Llata S: A new shunt for hydrocephalus that relies on CSF production rather than on ventricular pressure: initial clinical experiences. Surg Neurol 1995, 43:324–331. CrossRef
- Sotelo J: Update: the new ventriculoperitoneal shunt at the Institute of Neurology of Mexico. Surg Neurol 1996, 46:19–20. CrossRef
- Neal JH: An endoscopic approach to cysticercosis cysts of the posterior third ventricle. Neurosurgery 1995, 36:1040–1043. CrossRef
- Cudlip SA, Wilkins PR, Marsh HT: Endoscopic removal of a third ventricular cysticercal cyst. Br J Neurosurg 1998, 12:452–454. CrossRef
- Mohanty A, Venkatrama SK, Das S, et al.: Spinal intramedullary cysticercosis. Neurosurgery 1997, 40:82–87. CrossRef
- Garg RK, Nag D: Intramedullary spinal cysticercosis: response to albendazole: case reports and review of the literature. Spinal Cord 1998, 36:67–70. CrossRef
- Wilkins PP, Allan JC, Verastegui M, et al.: Development of a serologic assay to detect Taenia solium taeniasis. Am J Trop Med Hyg 1999, 60:199–204.
- Allan JC, Velasquez-Tohom M, Fletes C, et al.: Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg 1997, 91:595–598. CrossRef
- Sarti E, Flisser A, Schantz PM, et al.: Development and evaluation of a health education intervention against Taenia solium in a rural community in Mexico. Am J Trop Med Hyg 1997, 56:127–132.
- Gonzalez AE, Falcon N, Gavidia C, et al.: Treatment of porcine cysticercosis with oxfendazole: a dose-response trial. Vet Rec 1997, 141:420–422.
- Gauci CG, Flisser A, Lightowlers MW: A Taenia solium oncosphere protein homologous to host-protective Taenia ovis and Taenia saginata 18 kDa. Int J Parasitol 1998, 28:757–760. CrossRef
- Recent developments in the epidemiology, diagnosis, treatment, and prevention of neurocysticercosis
Current Infectious Disease Reports
Volume 1, Issue 5 , pp 434-440
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Infectious Disease Section, Departments of Medicine and Microbiology and Immunology, Baylor College of Medicine, One Baylor Plaza, 561E, 77030, Houston, TX, USA
- 2. Department of Microbiology, Universidad Peruana Cayetano Heredia, Department of Transmissible Diseases, Instituto de Ciencias, Neurologicas, Av. Honorio Delgado 430, Urb.Ingenieria, S.M.P., 31, Lima, Peru